FIELD: medicine, pharmacy. SUBSTANCE: invention proposes valeramide and the valeramide-containing pharmaceutical composition made as standardized medicinal form that can be administrated by oral, injection, cutaneous or mucosa route. For anxiety decrease and soporofic effect doses of valeramide are 1.50-20 and 10-20 mg/kg body mass, respectively. When isovaleramide is used as an agent causing anxiolytic effect then nondesirable sedative-hypnotic effect is absent that will ensure to use its as a component of light psychotherapeutic drugs. Valeramide can be used for decrease of anxiety state and sleep inducing in human and domestic animals. EFFECT: enhanced effectiveness of valeramide. 13 cl, 4 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOVALERAMIDE AS ANTISPATIC AND ANTICONVULSANT AGENT, EXTRACT FROM PLANT OF VALERIANACEACE FAMILY AND HOP AS AGENT FOR TREATMENT OF SPASTICITY SYMPTOM AND METHOD FOR ELIMINATION OF THIS SYMPTOM, METHOD FOR TREATMENT OF PATHOLOGY ELIMINATED BY CENTRALLY-MEDIATED REDUCING MUSCLE TONUS | 1997 |
|
RU2232016C2 |
| SEDATIVE AGENT | 2005 |
|
RU2295955C1 |
| 4-(1-HYDROXY-1-METHYL-2-MORPHOLINOETHYL)BENZOIC AND 4-(1-HYDROXY-2-MORPHOLINOCYCLOHEXYL)BENZOIC ACIDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, POSSESSING ANXIOLYTIC ACTIVITY, AND METHOD OF OBTAINING THEREOF | 2012 |
|
RU2505536C1 |
| GUAIFENESIN-BASED SEDATIVE FOR SMALL PETS | 2018 |
|
RU2683936C1 |
| AGENT FOR TREATMENT OF ANXIETY PATIENTS | 1994 |
|
RU2142274C1 |
| AGENT POSSESSING ANXIOLYTIC ACTIVITY | 2015 |
|
RU2571286C1 |
| AGENT POSSESSING ANXIOLYTHIC ACTION, ON BASIS OF HYDROGENATED PYRIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND WAY OF ITS APPLICATION | 2007 |
|
RU2338533C1 |
| ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
| DRUG SHOWING ANXIOLYTIC, ANTIALCOHOLIC AND CEREBROPROTECTIVE EFFECTS | 1999 |
|
RU2145855C1 |
| SEDATIVE AND MUSCLE RELAXANT ACTION DRUG | 2019 |
|
RU2719376C1 |
